Upregulation of macrophage migration inhibitory factor (MIF) and CD74, receptor for MIF, in rat bladder during persistent cyclophosphamide-induced inflammation

被引:27
|
作者
Vera, Pedro L. [1 ]
Wang, Xihai [1 ,2 ]
Meyer-Siegler, Katherine L. [1 ,2 ]
机构
[1] Bay Pines VA Healthcare Syst, Res & Dev 151, Bay Pines, FL 33744 USA
[2] Univ S Florida, Dept Surg, Tampa, FL 33612 USA
关键词
bladder; inflammation; cytokines; cox-2;
D O I
10.3181/0709-RM-240
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The objective of this study was to determine if macrophage migration inhibitory factor (MIF) is upregulated in the bladder during persistent cystitis. MIF is a pro-inflammatory cytokine found pre-formed in the urothelium. Previous findings showed that acute bladder inflammation increased MIF release into the bladder lumen while upregulating MIF and CD74 (MIF receptor) in the bladder. Because the effects of persistent cystitis on MIF and CD74 are not known, MIF and CD74 changes in the bladder were examined after short-term (1-day) or persistent (8-day) cyclophosphamide (CYP)-induced bladder inflammation. Anesthetized male Sprague-Dawley rats received either a single CYP treatment (150 mg/kg, ip; saline, control) and examined 1 day after treatment (short-term), or repeated CYP doses (20-75 mg/ kg, ip; saline, control; every third day for 8 days) and examined after 8 days of treatment (persistent). MIF protein levels in urine and bladder were determined. In addition, Mif CD74, and cox-2 expression in the bladder was determined. Histology verified cystitis and MIF and CD74 immunoreactivity in the bladder. Repeated CYP doses were decreased to avoid toxicity. Shortterm or repeated low CYP doses (40 mg/kg; 8 days) increased urinary MIF and decreased bladder MIF amounts while upregulating bladder Mif and CD74 mRNA expression. Persistent CYP-induced bladder inflammation (even at 40 mg/kg; 8-day treatment) also upregulated other inflammatory cytokines (CCL5, IL-11, iNOS) in the bladder. Short-term and persistent (low dose) CYP cystitis are associated with markedly increased MIF release into the urine and upregulation of Mif and CD74 in bladder. This supports the hypothesis that MIF and CD74 play a significant role in both acute and persistent stages of bladder inflammation.
引用
收藏
页码:620 / 626
页数:7
相关论文
共 50 条
  • [41] The role of macrophage migration inhibitory factor family and CD74 in the pathogenesis of melanoma
    Tanese, Keiji
    Ogata, Dai
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (06)
  • [42] Macrophage migration inhibitory factor and its receptor CD74 are upregulated in the urothelium of interstitial cystitis patients
    Vera, PL
    Pines, B
    Iczkowski, KA
    Moldwin, RM
    Kushner, L
    Meyer-Siegler, KL
    JOURNAL OF UROLOGY, 2006, 175 (04): : 95 - 96
  • [43] Macrophage migration inhibitory factor activates inflammatory responses of astrocytes through interaction with CD74 receptor
    Su, Yu
    Wang, Yingjie
    Zhou, Yue
    Zhu, Zhenjie
    Zhang, Qing
    Zhang, Xuejie
    Wang, Wenjuan
    Gu, Xiaosong
    Guo, Aisong
    Wang, Yongjun
    ONCOTARGET, 2017, 8 (02) : 2719 - 2730
  • [44] Macrophage migration inhibitory factor (MIF) expression by rat islets and its role in insulitis
    Kwon, G
    Vest, DK
    Xu, G
    Hill, JR
    Shure, D
    McDaniel, ML
    DIABETES, 1998, 47 : A251 - A251
  • [45] PURIFICATION TO HOMOGENEITY OF A MACROPHAGE GLYCOLIPID, A PUTATIVE RECEPTOR FOR MIGRATION-INHIBITORY FACTOR (MIF)
    LIU, DY
    PETSCHEK, KD
    REMOLD, HG
    DAVID, JR
    FEDERATION PROCEEDINGS, 1980, 39 (06) : 2183 - 2183
  • [46] Augmented expression of macrophage migration inhibitory factor (MIF) in the telencephalon of the developing rat brain
    Suzuki, T
    Ogata, A
    Tashiro, K
    Nagashima, K
    Tamura, M
    Nishihira, J
    BRAIN RESEARCH, 1999, 816 (02) : 457 - 462
  • [47] Blockade of macrophage migration inhibitory factor (MIF) inhibits rat crescentic glomerulonephritis (GN).
    Lan, HY
    Bacher, M
    Mu, W
    Yang, NS
    NikolicPaterson, DJ
    Metz, C
    Meinhardt, A
    Bucala, R
    Atkins, RC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A2302 - A2302
  • [48] Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): Use of biologically active labeled MIF derivatives
    Kleemann, R
    Grell, M
    Mishcke, R
    Zimmermann, G
    Bernhagen, J
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2002, 22 (03): : 351 - 363
  • [49] Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
    Wallace, Daniel J.
    Figueras, Florence
    Wegener, William A.
    Goldenberg, David M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) : 954 - 955
  • [50] The vascular biology of macrophage migration inhibitory factor (MIF) Expression and effects in inflammation, atherogenesis and angiogenesis
    Asare, Yaw
    Schmitt, Martin
    Bernhagen, Juergen
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (03) : 391 - 398